semaglutide deaths and Cardiovascular Outcomes in Obesity without Diabetes FDA Approves Semaglutide to Reduce

Addressing habitual eating patterns and reinforcing healthy behaviors through a comprehensive plan that includes nutrition guidance and mental health support is also important

Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, Di Salvo J, Epifani R, Piacevole A, Tagliaferri G, Rocco M, Iadicicco I, Docimo G, Rinaldi L, Sardu C, Salvatore T, Marfella R, Sasso FC (2023) Peripheral neuropathy in diabetes Mellitus: pathogenetic mechanisms and diagnostic options

Cardiovasc Diabetol 19(1):10 Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI (2018) Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Good injection technique matters, but consistency matters just as much

It is not FDA-approved and not available outside clinical trials